Wachter, Rolf

[["dc.bibliographiccitation.firstpage","540"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Biomarkers"],["dc.bibliographiccitation.lastpage","550"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Baldassarri, Flavia"],["dc.contributor.author","Schwedhelm, Edzard"],["dc.contributor.author","Atzler, Dorothee"],["dc.contributor.author","Böger, Rainer H."],["dc.contributor.author","Cordts, Kathrin"],["dc.contributor.author","Haller, Bernhard"],["dc.contributor.author","Pressler, Axel"],["dc.contributor.author","Müller, Stephan"],["dc.contributor.author","Suchy, Christiane"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Düngen, Hans-Dirk"],["dc.contributor.author","Hasenfuss, Gerd"],["dc.contributor.author","Pieske, Burkert"],["dc.contributor.author","Halle, Martin"],["dc.contributor.author","Edelmann, Frank"],["dc.contributor.author","Duvinage, André"],["dc.date.accessioned","2020-12-10T18:15:03Z"],["dc.date.available","2020-12-10T18:15:03Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1080/1354750X.2018.1460762"],["dc.identifier.eissn","1366-5804"],["dc.identifier.issn","1354-750X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/74724"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Relationship between exercise intervention and NO pathway in patients with heart failure with preserved ejection fraction"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1067"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","European Journal of Heart Failure"],["dc.bibliographiccitation.lastpage","1074"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Edelmann, Frank"],["dc.contributor.author","Bobenko, Anna"],["dc.contributor.author","Gelbrich, Götz"],["dc.contributor.author","Hasenfuss, Gerd"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Duvinage, André"],["dc.contributor.author","Schwarz, Silja"],["dc.contributor.author","Mende, Meinhard"],["dc.contributor.author","Prettin, Christiane"],["dc.contributor.author","Trippel, Tobias"],["dc.contributor.author","Lindhorst, Ruhdja"],["dc.contributor.author","Morris, Daniel"],["dc.contributor.author","Pieske-Kraigher, Elisabeth"],["dc.contributor.author","Nolte, Kathleen"],["dc.contributor.author","Düngen, Hans-Dirk"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Halle, Martin"],["dc.contributor.author","Pieske, Burkert"],["dc.date.accessioned","2018-04-23T11:48:12Z"],["dc.date.available","2018-04-23T11:48:12Z"],["dc.date.issued","2017"],["dc.description.abstract","Heart failure with preserved ejection fraction (HFpEF) is a common disease with high incidence and increasing prevalence. Patients suffer from functional limitation, poor health‐related quality of life, and reduced prognosis. A pilot study in a smaller group of HFpEF patients showed that structured, supervised exercise training (ET) improves maximal exercise capacity, diastolic function, and physical quality of life. However, the long‐term effects of ET on patient‐related outcomes remain unclear in HFpEF. The primary objective of the Exercise training in Diastolic Heart Failure (Ex‐DHF) trial is to investigate whether a 12 month supervised ET can improve a clinically meaningful composite outcome score in HFpEF patients. Components of the outcome score are all‐cause mortality, hospitalizations, NYHA functional class, global self‐rated health, maximal exercise capacity, and diastolic function. After undergoing baseline assessments to determine whether ET can be performed safely, 320 patients at 11 trial sites with stable HFpEF are randomized 1:1 to supervised ET in addition to usual care or to usual care alone. Patients randomized to ET perform supervised endurance/resistance ET (3 times/week at a certified training centre) for 12 months. At baseline and during follow‐up, anthropometry, echocardiography, cardiopulmonary exercise testing, and health‐related quality of life evaluation are performed. Blood samples are collected to examine various biomarkers. Overall physical activity, training sessions, and adherence are monitored and documented throughout the study using patient diaries, heart rate monitors, and accelerometers. The Ex‐DHF trial is the first multicentre trial to assess the long‐term effects of a supervised ET programme on different outcome measures in patients with HFpEF."],["dc.identifier.doi","10.1002/ejhf.862"],["dc.identifier.gro","3142337"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/13472"],["dc.language.iso","en"],["dc.notes.intern","lifescience updates Crossref Import"],["dc.notes.status","final"],["dc.relation.issn","1388-9842"],["dc.title","Exercise training in Diastolic Heart Failure (Ex-DHF): rationale and design of a multicentre, prospective, randomized, controlled, parallel group trial"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","53"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","ESC Heart Failure"],["dc.bibliographiccitation.lastpage","62"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Bobenko, Anna"],["dc.contributor.author","Bartels, Inke"],["dc.contributor.author","Münch, Marlene"],["dc.contributor.author","Trippel, Tobias"],["dc.contributor.author","Lindhorst, Ruhdja"],["dc.contributor.author","Nolte, Kathleen"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Halle, Martin"],["dc.contributor.author","Duvinage, André"],["dc.contributor.author","Düngen, Hans-Dirk"],["dc.contributor.author","Gelbrich, Götz"],["dc.contributor.author","Tschöpe, Carsten"],["dc.contributor.author","Hasenfuss, Gerd"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Pieske, Burkert"],["dc.contributor.author","Edelmann, Frank"],["dc.date.accessioned","2018-04-23T11:48:01Z"],["dc.date.available","2018-04-23T11:48:01Z"],["dc.date.issued","2018"],["dc.description.abstract","Aims Heart failure with preserved ejection fraction (HFpEF) remains a common condition with no pharmacological treatment. Physical activity (PA) improves symptoms and quality of life (QoL), but no clear recommendations exist on PA in HFpEF patients. We investigated the association of PA (amount/intensity) on clinical phenotype in HFpEF. Methods and results The Aldosterone in Diastolic Heart Failure trial investigated spironolactone vs. placebo in stable HFpEF patients. At baseline, all patients underwent detailed phenotypization including echocardiography, cardiopulmonary exercise testing, 6 minute walking test (6MWT), and QoL assessment (36‐item Short‐Form questionnaire). PA was assessed by a self‐report questionnaire, classified in metabolic equivalents of task (MET) and analysed with regard to exercise capacity, diastolic function, and QoL. Four hundred twenty‐two patients (52% women, age 67 ± 8 years, New York Heart Association II and III) were classified by weekly MET hours into a low (<70), middle (70–140), or high (>140) level of PA. Total PA correlated positively with 6MWT distance (r = 0.17; P = 0.002) and physical function of QoL (r = 0.10; P = 0.05), but not with peak oxygen uptake (peakVO2). In contrast, both 6MWT distance and peakVO2 were significantly higher in patients who performed high‐intensity PA for >8 h/week (P < 0.001, P = 0.02, respectively). Time of high‐intensity PA was related to higher 6MWT distance (r = 0.21, P < 0.001), peakVO2, and better physical function of QoL (both r = 0.13, P = 0.01), whereas low‐intensity PA did not show significant associations. Interestingly, PA was not related to any measure of diastolic function. Conclusions A higher amount of PA is related to higher submaximal exercise capacity and physical function of QoL. Regarding maximal exercise capacity, only high‐intensity PA showed significant association in HFpEF patients."],["dc.identifier.doi","10.1002/ehf2.12227"],["dc.identifier.gro","3142318"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/13451"],["dc.language.iso","en"],["dc.notes.intern","lifescience updates Crossref Import"],["dc.notes.status","final"],["dc.relation.issn","2055-5822"],["dc.title","Amount or intensity? Potential targets of exercise interventions in patients with heart failure with preserved ejection fraction"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Clinical Research in Cardiology"],["dc.contributor.author","Lechner, Katharina"],["dc.contributor.author","Scherr, Johannes"],["dc.contributor.author","Lorenz, Elke"],["dc.contributor.author","Lechner, Benjamin"],["dc.contributor.author","Haller, Bernhard"],["dc.contributor.author","Krannich, Alexander"],["dc.contributor.author","Halle, Martin"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Duvinage, André"],["dc.contributor.author","Edelmann, Frank"],["dc.date.accessioned","2021-10-01T09:58:53Z"],["dc.date.available","2021-10-01T09:58:53Z"],["dc.date.issued","2021"],["dc.description.abstract","Abstract Objectives To evaluate associations of omega-3 fatty acid (O3-FA) blood levels with cardiometabolic risk markers, functional capacity and cardiac function/morphology in patients with heart failure with preserved ejection fraction (HFpEF). Background O3-FA have been linked to reduced risk for HF and associated phenotypic traits in experimental/clinical studies. Methods This is a cross-sectional analysis of data from the Aldo-DHF-RCT. From 422 patients, the omega-3-index (O3I = EPA + DHA) was analyzed at baseline in n  = 404 using the HS-Omega-3-Index ® methodology. Patient characteristics were; 67 ± 8 years, 53% female, NYHA II/III (87/13%), ejection fraction ≥ 50%, E / e ′ 7.1 ± 1.5; median NT-proBNP 158 ng/L (IQR 82–298). Pearson’s correlation coefficient and multiple linear regression analyses, using sex and age as covariates, were used to describe associations of the O3I with metabolic phenotype, functional capacity, echocardiographic markers for LVDF, and neurohumoral activation at baseline/12 months. Results The O3I was below (< 8%), within (8–11%), and higher (> 11%) than the target range in 374 (93%), 29 (7%), and 1 (0.2%) patients, respectively. Mean O3I was 5.7 ± 1.7%. The O3I was inversely associated with HbA1c ( r  = − 0.139, p  = 0.006), triglycerides-to-HDL-C ratio ( r  = − 0.12, p  = 0.017), triglycerides ( r  = − 0.117, p  = 0.02), non-HDL-C ( r  = − 0.101, p  = 0.044), body-mass-index ( r  = − 0.149, p  = 0.003), waist circumference ( r  = − 0.121, p  = 0.015), waist-to-height ratio ( r  = − 0.141, p  = 0.005), and positively associated with submaximal aerobic capacity ( r  = 0.113, p  = 0.023) and LVEF ( r  = 0.211, p  < 0.001) at baseline. Higher O3I at baseline was predictive of submaximal aerobic capacity ( β  = 15.614, p  < 0,001), maximal aerobic capacity ( β  = 0.399, p  = 0.005) and LVEF ( β  = 0.698, p  = 0.007) at 12 months. Conclusions Higher O3I was associated with a more favorable cardiometabolic risk profile and predictive of higher submaximal/maximal aerobic capacity and lower BMI/truncal adiposity in HFpEF patients. Graphic abstract Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients. Higher O3I was associated with a more favorable cardiometabolic risk profile and aerobic capacity (left) but did not correlate with echocardiographic markers for left ventricular diastolic function or neurohumoral activation (right). An O3I-driven intervention trial might be warranted to answer the question whether O3-FA in therapeutic doses (with the target O3I 8–11%) impact on echocardiographic markers for left ventricular diastolic function and neurohumoral activation in patients with HFpEF. This figure contains modified images from Servier Medical Art ( https://smart.servier.com ) licensed by a Creative Commons Attribution 3.0 Unported License."],["dc.description.abstract","Abstract Objectives To evaluate associations of omega-3 fatty acid (O3-FA) blood levels with cardiometabolic risk markers, functional capacity and cardiac function/morphology in patients with heart failure with preserved ejection fraction (HFpEF). Background O3-FA have been linked to reduced risk for HF and associated phenotypic traits in experimental/clinical studies. Methods This is a cross-sectional analysis of data from the Aldo-DHF-RCT. From 422 patients, the omega-3-index (O3I = EPA + DHA) was analyzed at baseline in n  = 404 using the HS-Omega-3-Index ® methodology. Patient characteristics were; 67 ± 8 years, 53% female, NYHA II/III (87/13%), ejection fraction ≥ 50%, E / e ′ 7.1 ± 1.5; median NT-proBNP 158 ng/L (IQR 82–298). Pearson’s correlation coefficient and multiple linear regression analyses, using sex and age as covariates, were used to describe associations of the O3I with metabolic phenotype, functional capacity, echocardiographic markers for LVDF, and neurohumoral activation at baseline/12 months. Results The O3I was below (< 8%), within (8–11%), and higher (> 11%) than the target range in 374 (93%), 29 (7%), and 1 (0.2%) patients, respectively. Mean O3I was 5.7 ± 1.7%. The O3I was inversely associated with HbA1c ( r  = − 0.139, p  = 0.006), triglycerides-to-HDL-C ratio ( r  = − 0.12, p  = 0.017), triglycerides ( r  = − 0.117, p  = 0.02), non-HDL-C ( r  = − 0.101, p  = 0.044), body-mass-index ( r  = − 0.149, p  = 0.003), waist circumference ( r  = − 0.121, p  = 0.015), waist-to-height ratio ( r  = − 0.141, p  = 0.005), and positively associated with submaximal aerobic capacity ( r  = 0.113, p  = 0.023) and LVEF ( r  = 0.211, p  < 0.001) at baseline. Higher O3I at baseline was predictive of submaximal aerobic capacity ( β  = 15.614, p  < 0,001), maximal aerobic capacity ( β  = 0.399, p  = 0.005) and LVEF ( β  = 0.698, p  = 0.007) at 12 months. Conclusions Higher O3I was associated with a more favorable cardiometabolic risk profile and predictive of higher submaximal/maximal aerobic capacity and lower BMI/truncal adiposity in HFpEF patients. Graphic abstract Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients. Higher O3I was associated with a more favorable cardiometabolic risk profile and aerobic capacity (left) but did not correlate with echocardiographic markers for left ventricular diastolic function or neurohumoral activation (right). An O3I-driven intervention trial might be warranted to answer the question whether O3-FA in therapeutic doses (with the target O3I 8–11%) impact on echocardiographic markers for left ventricular diastolic function and neurohumoral activation in patients with HFpEF. This figure contains modified images from Servier Medical Art ( https://smart.servier.com ) licensed by a Creative Commons Attribution 3.0 Unported License."],["dc.identifier.doi","10.1007/s00392-021-01925-9"],["dc.identifier.pii","1925"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/90166"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-469"],["dc.relation.eissn","1861-0692"],["dc.relation.issn","1861-0684"],["dc.title","Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients: the Aldo-DHF randomized controlled trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]